Headlines

Boston Scientific Corporation (BSX) Q4 2025 (USD): adj. EPS 0.80 (exp. 0.78), Revenue 5.29bln (exp. 5.28bln)

Newsquawk Staff ·

GUIDANCE

  • Q1 Rev. growth view +10.5-12.0% (exp. 5.21bln)
  • FY EPS view 3.43-3.49 (exp. 3.47)

What it means

Boston Scientific's Q4 earnings slightly beat expectations on both adjusted EPS and revenue, which could lend positive momentum to their stock. Their strong guidance for Q1 revenue growth and full-year EPS suggests continued confidence in their growth trajectory, potentially signaling strength in the healthcare equipment sector and influencing broader market sentiment.

Related headlines